{"event":{"category":"Financials","collateral_return_type":"MECNET","event_ticker":"KXVENGLUSTAT-27","exchange_index":0,"last_updated_ts":"2026-10-28T06:26:53.505873Z","mutually_exclusive":true,"series_ticker":"KXVENGLUSTAT","settlement_sources":[{"name":"AppliedXL","url":"https://www.appliedxl.com/"}],"strike_period":"","sub_title":"FDA decision on Venglustat in 2026","title":"FDA decision: Venglustat by Sanofi (in 2026)"},"markets":[{"can_close_early":true,"close_time":"2026-11-19T00:45:35Z","created_time":"2026-06-17T20:30:11.53077Z","early_close_condition":"This market will close early if the FDA issues a decision on Venglustat before Jan 1, 2027","event_ticker":"KXVENGLUSTAT-27","exchange_index":0,"expected_expiration_time":"2027-01-01T15:00:00Z","expiration_value":"Yes","last_price_dollars":"0.8600","latest_expiration_time":"2027-01-08T15:00:00Z","market_type":"binary","no_ask_dollars":"1.0000","no_bid_dollars":"0.0000","no_sub_title":"a full approval or an accelerated approval","notional_value_dollars":"1.0000","occurrence_datetime":"2026-11-19T01:00:00Z","open_interest_fp":"1419.17","open_time":"2026-06-17T21:00:00Z","previous_price_dollars":"0.8600","previous_yes_ask_dollars":"1.0000","previous_yes_bid_dollars":"0.0000","price_level_structure":"linear_cent","price_ranges":[{"end":"1.0000","start":"0.0000","step":"0.0100"}],"result":"yes","rules_primary":"If the FDA's decision on Venglustat by Sanofi in 2026 is a full approval or an accelerated approval, the market resolves to Yes.","rules_secondary":"This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. \n\nVenglustat is an oral small-molecule drug developed by Sanofi that works by slowing down the body's production of a fatty substance called glucosylceramide, which builds up to harmful levels in people with Gaucher disease — think of it like adjusting a factory's output dial rather than cleaning up the mess after the fact. It belongs to a class called substrate reduction therapy (SRT), meaning it targets the upstream source of the problem rather than replacing a missing enzyme. Because it is a small molecule taken by mouth and designed to cross into the brain, it has potential to address the neurological symptoms that older enzyme-based treatments cannot reach.\n","settlement_bounds_type":"default","settlement_timer_seconds":1800,"settlement_ts":"2026-11-19T01:15:40.008956Z","settlement_value_dollars":"1.0000","status":"finalized","ticker":"KXVENGLUSTAT-27-Y","title":"What will the FDA's decision be on Venglustat by Sanofi in 2026?","updated_time":"2026-11-19T01:15:40.472754Z","volume_24h_fp":"0.00","volume_fp":"2120.91","yes_ask_dollars":"1.0000","yes_ask_size_fp":"0.00","yes_bid_dollars":"0.0000","yes_bid_size_fp":"0.00","yes_sub_title":"a full approval or an accelerated approval"}]}
